



OPEN ACCESS

How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines

Isaac Bai ,¹ Peter Doshi ,² Matthew Herder^{3,4}

10.1136/bmjebm-2023-112475

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjebm-2023-112475>).

¹Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

²Department of Practice, Sciences, and Health Outcomes Research, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA

³Health Law Institute, Schulich School of Law, Dalhousie University, Halifax, Nova Scotia, Canada

⁴Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Correspondence to: **Isaac Bai**, Dalhousie Medical School, Halifax, Canada; ibai@dal.ca



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Bai I, Doshi P, Herder M. *BMJ Evidence-Based Medicine* 2024;**29**:187–193.

Abstract

Incorporating clinical data held by national health product regulatory authorities into secondary analyses such as systematic reviews can help combat publication bias and selective outcome reporting, in turn, supporting more evidence-based decisions regarding the prescribing of drugs, biologics and vaccines. Owing to recent changes in Canadian law, Health Canada has begun to make clinical information—whether it has been previously published or not—publicly available through its ‘Public Release of Clinical Information’ (PRCI) online database. We provide guidance about how to access and use regulatory data obtained through the PRCI database for the purpose of conducting drug and biologic secondary analyses.

Introduction

Secondary analyses such as systematic reviews and trial reanalyses are usually conducted using publicly reported data (especially journal publications). However, journal publications often contain relatively limited information, for example, about the design of a clinical trial. Further, factors such as publication bias and selective outcome reporting often lead to overstating efficacy and understating the harms.^{1 2} Statistical methods exist to detect the likelihood of publication bias, but no single test can reliably rule it out.³ Direct access to unpublished data is arguably the only way to fully overcome publication bias. Selective reporting bias (biases that distort the proper interpretation of published trials) generally can only be detected by comparing two or more sources of information (eg, journal publication vs ClinicalTrials.gov vs regulatory data).⁴ Yet, registration on ClinicalTrials.gov is only mandatory for trials of FDA-regulated products with at least one trial site in the USA,⁵ and compliance with registration and results reporting requirements remains imperfect. For instance, one study showed that 59% of trials had not posted results on ClinicalTrials.gov 2 years after completion.⁶ Another study of 400 trials registered on ClinicalTrials.gov found only 58% had their primary outcomes adequately described.⁷

In this environment, health product regulators have emerged as an important source of data for secondary analyses.^{4 8 9} Since 1998, the US Food and Drug Administration (FDA) has published its scientific reviews on drug approval^{10 11} through its Drugs@FDA database. These reviews

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Most secondary analyses are conducted based on published trials which can be influenced by publication bias and selective reporting bias. Incorporation of data from regulators may substantially change the conclusions of secondary analyses.

WHAT THIS STUDY ADDS

⇒ This study provides guidance on how to access and use regulatory data obtained through Health Canada's Public Release of Clinical Information (PRCI) online database for the purpose of conducting secondary analyses for drugs, biologics, and vaccines.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Incorporating the regulatory data from the PRCI database into secondary analyses has the potential to significantly improve evidence-based medicine.

frequently contain more data than published literature, including key details of trial designs and outcomes, and the regulator's interpretations of a drug's safety, efficacy and quality. More recently, other regulators, namely, the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and Health Canada (HC), have been empowered to publicly disclose portions of the regulatory dossiers submitted by manufacturers when seeking regulatory approval. While Drugs@FDA often contains important elements from a regulatory dossier, such as trials' summary results statistics and additional FDA-initiated analyses,¹¹ the EMA, PMDA and HC publish the original industry documents submitted to the regulator—for example, Clinical Summaries, Clinical Study Reports (CSRs), adverse event narratives, trial protocols and statistical analysis plans—essentially in their entirety although with some redactions (table 1).

Despite the wealth of data that can now be secured from regulators, there is little sign that researchers engaged in systematic reviews and other secondary analyses routinely incorporate

Table 1 Characteristics of regulatory data released by Canadian, European, USA and Japanese regulators*

	HC	EMA	US FDA	Japan PMDA
Year of inception	2019	2010 (Policy 0043), 2015 (Policy 0070)	1998	Unclear
Types of submissions disclosed†	New submissions (after March 2019) and past submissions (any year not covered by new submissions)	New submissions (Policy 0070; After January 2015 for market authorisation application or Article 58 procedure; July 2015 for line extension or new indication) and past submissions (Policy 0043; any year not covered by new submissions)	New and past submissions, which can be requested through the Freedom of Information Act; 1938 to present	New and past submissions
Scope of submissions disclosed	Approved, unapproved or withdrawn products	Approved, unapproved or withdrawn products	Approved products	Approved products
Types of documents	Original documents submitted by manufacturers	Original documents submitted by manufacturers	Summaries and reviews written by FDA staff (Public access); original documents submitted by manufacturers (via Freedom of Information Act request only)	Summaries and reviews written by PMDA staff; original documents submitted by manufacturers. Most were in Japanese with some reviews in English translation
How to access	HC Public Release of Clinical Information portal	EMA clinical data sharing portal	Drugs@FDA portal (summaries and reviews only); direct request (original documents submitted by manufacturers)	Variety of webpages on PMDA website
URLs	https:// clinical-information.canada.ca	https:// clinicaldata.ema.europa.eu	https:// www.fda.gov/drugsatfda	https:// www.pmda.go.jp/english/ search_index.html (English) https:// www.pmda.go.jp/PmdaSearch/iyakuSearch/ (Japanese)
Who can access	Public	Public (new submissions); requesters (past submissions; restricted to European Union members only)	Public (summaries and reviews only); requesters (original documents submitted by manufacturers)	Public

*Data sources: we consulted Egilman *et al*²³ in addition to searching regulatory websites.
 †New submissions refer to ones that enter the market prior to the inception of the databases, whereas old submissions refer to ones that are available before the launch of the databases.
 EMA, European Medicines Agency; FDA, Food and Drug Administration; HC, Health Canada; PMDA, Pharmaceuticals and Medical Devices Agency.

data from regulatory sources.^{12 13} This likely stems from insufficient awareness of document availability as well as practical barriers to using regulatory-sourced data. Reports obtained from regulators can range up to thousands of pages in length, which may require tremendous time and resources from systematic reviewers.^{12 14} However, these barriers can be mitigated, in part, with guidance about how to access and use these data.¹² In addition, when research misconduct is identified by regulators, there does not appear to be communication between the regulators and journals, as one study found no subsequent corrections to 57 studies published in the literature that FDA identified as having research conduct issues.¹⁵ In another instance, the publication of a major cardiovascular drug trial went uncorrected even after FDA reviewers judged the data unreliable a decade prior.¹⁶ These are additional reasons to have access to regulatory data, even for published studies.

To date, efforts have been made to provide experience and guidance on the use of regulatory data that were obtained through the Drugs@FDA database^{10 17} and EMA’s Policy 0070.^{18 19} Apart from HC’s own highly technical guidance,²⁰ however, there is no published literature that explains the scope and holdings of HC’s ‘Public Release of Clinical Information’

(PRCI) online database. This is a critical gap in the literature because the PRCI database has important comparative advantages. First, Canada is releasing not only approved products but also ones rejected from market entry (table 1). Second, Canada allows anyone to download data without registration (EMA has restricted downloads to European Union residents only).²¹ Third, Canada’s holding include medical devices, not just drugs and vaccines. This Research Methods and Reporting article aims to fill this gap in the literature, detailing what the Canadian database contains and how it can be accessed.

Methods

The PRCI portal was comprehensively reviewed in March 2022, and 203 clinical information packages pertaining to drugs and biologics (excluding medical devices) were identified that were publicly released between March 2019 and March 2022 via the HC PRCI database. Information contained in the drug/biologic packages was charted based on their contents, submission types, authorisation types, initial regulatory decision dates and public release dates (table 2). Relevant policy materials such as HC’s PRCI guidance document²⁰ and the terms and conditions page from the PRCI database was reviewed and summarised to provide further

Table 2 Characteristics of the 203 clinical information packages released between March 2019 and March 2022

	Number of packages
Total clinical information packages	203
By product type	
Small molecule drug	137 (67%)
Biologic	44 (22%)
Vaccine	20 (10%)
Radiopharmaceutical	2 (1%)
By decision date	
Before 2003	21
2003–2018	49
2019–present	133
By submission type	
New applications (NDS, NDS-NAS)	137
Supplemental applications (SNDS, SNDS-c)	54
Generic drug applications (ANDS)	2
Interim order	10
By authorisation type	
NOC	191
Authorised with conditions	10
NOD-W	2
ANDS, abbreviated new drug submission; NDS, new drug submission; NDS-NAS, new drug submission-new active substance; NOC, notice of compliance; NOD-W, notice of deficiency-withdrawal; SNDS, supplement to a new drug submission; SNDS-c, supplement to a new drug submission containing confirmatory trials.	

context to the use of the information contained in the database. This article will explain the scope, terms of use and steps for accessing regulatory data from the database.

Results

What is contained in the database (what is the scope of PRCI)?

Table 3 provides a list of the typical documents released on PRCI. This means a wealth of clinical data is available for approved, rejected and withdrawn products, and anyone can access clinical information through the database without any sort of formal registration or application process.²² To access the data, a user must accept the terms of use, but the architects of the portal have made this a smooth and easy process in an effort to 'enable independent reanalysis of data and generate new research questions'.²⁰

PRCI's data availability is not restricted to a specific timeframe. Products approved, rejected or withdrawn prior to 2019 when the portal was launched can be disclosed following a request made via the portal. Approximately a third of the products listed on the database predate 2019, with one (metronidazole) dated as early as 1960. However, like submissions post-March 2019, once they are released, anyone anywhere in the world can access them for free via HC's portal website. Currently, more packages are available for post-2019 decisions, automatically published on reaching a decision, while pre-2019 decisions are typically published on request or at HC's discretion. The time from request to final disclosure likely depends on a variety of factors, but from early experience, one study demonstrated that when requests were made for hepatitis C drugs Harvoni and Sovaldi, it showed a timeframe of 918, 968 and 351 (Sovaldi)/155 (Harvoni) days, from request to disclosure by FDA, EMA, and HC, respectively.²³

What does each clinical information package contain?

Generally, each package contains three main types of documents: a Clinical Overview, Clinical Summaries and CSRs. All three of these documents, especially CSRs, can be useful for secondary research and tend to provide more accurate and complete information about a drug's safety and/or efficacy profile relative to corresponding studies in the published literature.^{4 18}

First, the Clinical Overview is usually a single PDF document containing a high-level summary of relevant information pertaining to the drug of interest, including but not limited to the product development rationale, biopharmaceutics, pharmacology, efficacy/safety studies and benefit/risk assessment. This section should provide a complete list of all clinical studies of the drug, since the initiation of premarketing studies almost always requires regulatory approval. Information presented in this module can be cross-referenced to more detailed information found in subsequent modules.

Second, Clinical Summaries are usually divided into four parts: the Summary of Biopharmaceutic Studies and Associated Analytical Methods; the Summary of Clinical Pharmacology Studies; the Summary of Clinical Efficacy; and the Summary of Clinical Safety. Each part typically contains one single PDF document, and provides a summary of methods, results and conclusions of all included studies for the submission, at the level more detailed than the Clinical Overview. More detailed information is cross-referenced to CSRs.

Third, CSRs contain unabridged reports of individual studies pertaining to the indication submitted to HC for marketing approval. Each individual CSR may contain separate PDF files for the main report body, the protocol and amendments, statistical methods, sample case report forms, and various adverse event narrative files.

These documents can be expected to be the same as those submitted to other regulators such as FDA and EMA, particularly since 2003 after which submissions will typically be organised to follow the International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Common Technical Document (CTD) and Electronic Common Technical Document (eCTD) format.²⁴

The organisation of each package varies, in part, because the amount of information submitted by manufacturers to HC itself varies due to varying regulatory requirements applicable to, for instance, new active substances versus a generic drug submission. The packages also vary because the format of product submissions has evolved over time; more variation is seen prior to the 2003 adoption of the ICH standards.

For drugs that received final regulatory decisions before 2003, the clinical information packages may present differently. Older packages tend to contain scanned PDF documents that may not be searchable without first performing optical character recognition (OCR). However, manual OCR'ing of documents may not be required as some newer computers and software automatically perform OCR on scanned PDF documents without special OCR software.

Information contained in the packages are subject to anonymisation and redaction, primarily to protect personal information and reduce the risk of reidentification of study participants. The anonymisation report is also disclosed as part of each package posted on the PRCI portal. There are two categories of clinical information that can be redacted by manufacturers (box 1). However, HC has the discretion to disclose these two categories of information as part of a submission packages unless

Table 3 List of common clinical information released in the Health Canada Public Release of Clinical Information database

CTD/eCTD module	Types of information	Description	Additional information for researchers
2.5	Clinical overview	Overview of product development rationale, biopharmaceutics, pharmacokinetics, efficacy, safety and benefit/risk conclusions.	Provides factual summary of clinical information and conclusion of critical analysis of the results, discussion and interpretation of clinical findings on pertinent studies.
2.7.1	Summary of biopharmaceutics and associated analytical methods	Summary of all in vitro or in vivo biopharmaceutic studies including their background/overview, methods, results and conclusion.	Provide a tabular listing of all corresponding (ie, biopharmaceutic, pharmacological, clinical efficacy, clinical safety) studies. Provide detailed factual summary of all studies included in the submission.
2.7.2	Summary of clinical pharmacology studies	Summary of all in vitro or in vivo PK and PD studies including their background/overview, methods, results and conclusion.	
2.7.3	Summary of clinical efficacy	Summary of all clinical studies conducted to evaluate efficacy (dose–response, comparative efficacy, long-term efficacy, and efficacy studies in population subsets), including their background/overview, methods, results and conclusion.	
2.7.4	Summary of clinical safety	Summary of data relevant to safety in the intended patient population, including results from individual CSRs and other relevant reports.	
5.3.1	Reports of biopharmaceutic studies	CSRs of studies evaluating rate and extent of release of the active substance from the medicinal product.	Provide a tabular listing of all corresponding biopharmaceutic, pharmacological, clinical efficacy, clinical safety) studies. Contain CSRs, protocol and amendments, statistical analysis plans, sample case report forms and individual adverse event narrative files. Maybe useful for: <ul style="list-style-type: none"> ▶ Incorporating unreported results and unpublished trials into a systematic review and/or meta-analysis. ▶ Critically appraising integrity of methods and results from corresponding published trials.
5.3.2	Reports of studies pertinent to pharmacokinetics using human biomaterials	Clinical study reports of in vitro or ex vivo studies using materials derived from human sources to evaluate PK properties of drug substances.	
5.3.3	Reports of human PK studies	in vivo PK studies.	
5.3.4	Reports of human PD studies	Reports of studies with a primary objective of determining the PD effects of a drug product.	
5.3.5	Reports of efficacy and safety studies	Reports of all clinical studies of efficacy and/or safety carried out with the drug, including all completed and all ongoing studies of the drug in proposed and non-proposed indications.	
5.3.6	Reports of postmarketing experience	Reports that summarise marketing experience, including all significant safety observations, for all products that are currently marketed.	

CSR, Clinical Study Report; CTD, Common Technical Document; eCTD, Electronic Common Technical Document; PD, pharmacodynamic; PK, pharmacokinetics.

manufacturers provide adequate justification.²⁵ It is worth noting that manufacturers are responsible for redaction and submitting the anonymised reports, and redactions may not be consistent across different manufacturers (box 2).

What information can be used for the purposes of secondary analysis?

Since the HC clinical information packages may contain multiple PDFs with thousands of pages, it is important to locate the information pertinent for the purpose of your secondary analysis. For researchers looking for information on efficacy and safety data, Summary of Clinical Efficacy and Summary of Clinical Safety, respectively, provide an overview and a list of all clinical studies (controlled and uncontrolled, and irrespective of whether the study has been published in the biomedical literature) submitted to HC for marketing decision. Therefore, it can serve as an excellent source when conducting a systematic search of literature. Additionally, these modules can be used to identify any potentially unpublished trials. For individual studies including their report bodies, protocols and amendments, and statistical methods, data can be found in CSRs (generally

found under ‘Reports of Efficacy and Safety Studies’). CSR and their numerous appendices contain substantially more details than the Summary modules and are suitable for critical appraisal of individual studies including the statistical methods, obtaining data from the studies for syntheses, and assessing changes in the protocols such as selective outcome reporting.²⁶ Some packages might contain Reports of Post-marketing Experience (listed as part of a ‘Post-Authorisation Activity Table’), which can be used to assess long-term safety outcomes. However, at the time of writing (April 2022), there is only one package available through the portal (for the drug mecasermin) that contains this type of information. Typically, additional data from postmarketing studies and/or pharmacovigilance must be secured independently from a different part of HC’s website.

For biopharmaceutics and analytical methods, data can be found in the Summary of Biopharmaceutic Studies and Associated Analytical Methods and Reports of Biopharmaceutic Studies. For information on pharmacology, data can be found in the Summary of Clinical Pharmacology Studies, Reports of Studies Pertinent to Pharmacokinetics Using Human Biomaterials, Reports of Human Pharmacokinetic (PK) Studies and

Box 1 Historical context of the PRCI database

Historically, information supplied by a manufacturer to HC was, as a matter of practice, treated as ‘confidential business information’ (CBI) that could not be publicly disclosed.²⁸ However, significant changes brought about by ‘Vanessa’s Law’, which Canada’s Parliament enacted in 2014, gave Health Canada (HC) the power to prescribe information as falling outside the scope of CBI. In 2019, HC used this new power to create a set of regulations that deemed information that had been considered CBI to no longer fall into that category once a decision to approve, reject or withdraw a drug, from the market.²¹ These regulations serve as the legal basis for the creation of the Public Release of Clinical Information (PRCI) portal.

Notably, some information continues to be treated as CBI; namely, (1) clinical information that was not used in the drug submission for the claimed indication (eg, exploratory outcome data to support future trials in obtaining a new indication); and (2) clinical information that describes tests, methods or assays that were used exclusively by a given manufacturer. According to HC policies, manufacturers are responsible for preparing the redaction version of documents and to provide an anonymisation report. A recent study found that the redactions in materials released by both HC and EMA primarily pertained to identifying details of trial investigators and participant ID numbers; such redactions may prevent certain analyses but generally still allow for the reanalysis of trial data.²³ It remains to be seen how widely or narrowly these exceptions from disclosure are being relied upon by manufacturers and/or granted by HC.

Box 2 Discrepancy in redactions of similar information

Below is an example showing the discrepancy in redaction practices between Moderna and Pfizer for a similar adverse event narrative file.²⁹ Moderna did not redact participant details (first picture) whereas Pfizer did³⁰ (second picture).

Moderna TX, Inc.
Protocol mRNA-1273-P203

Participant Number:	QF5230206
Vaccination Group:	100 µg mRNA-1273
Baseline SARS-CoV-2 Status:	Negative
First Dose of Vaccine:	10 Mar 2021
Second Dose of Vaccine:	07 Apr 2021
Reason for Narrative:	SAE

1. Screenshot of an adverse event narrative for the Moderna COVID-19 vaccine (mRNA-1273).

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Other SAE
Unique Subject ID: PPD; Country: PPD
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: PPD; Date of Last Dose: PPD

2. Screenshot of an adverse event narrative for the Pfizer COVID-19 vaccine (BNT162b2).

Reports of Human Pharmacodynamic (PD) Studies (table 3). These two sections may not be relevant for most researchers looking for clinical efficacy and safety data. However, the biopharmaceutics modules may contain data on drug interactions and the pharmacology modules may contain data on initial tolerability, which can both be used to supplement assessment on drug safety. Additionally, immune response data for biologics and vaccines can be found in the pharmacology modules.

Regardless of the type of data you are looking for, Reports of Analyses of Data from More than One Study and Other Study Reports may contain relevant information that are not found in other modules, including but not limited to data from non-pivotal trials, trials for a different population, or trials for a different indication.

How do I access the data?

To access and download clinical information packages on HC’s website:

1. Start by going to the Health Canada Public Release of Clinical Information (<https://clinical-information.canada.ca>) website (online supplemental figure 1).
2. The packages can be accessed either directly from the list (online supplemental figure 2, box) or through the search (online supplemental figure 2, circle). Either a brand name or generic name can be used for searches. Search results can be narrowed using the filters. In this case, remdesivir is used as an example.
3. There may be multiple search results for a single drug, with each representing a separate submission/indication to HC for marketing approval, denoted by a unique ‘submission control number’ (online supplemental figure 3).
4. Inside the packages, each link represents a separate PDF file that can be downloaded. If desired, all PDFs within the same package can be downloaded all at once as a compressed ZIP file under ‘Submission archive’–‘Download ZIP’ (online supplemental figure 4).

Clinical information for products regulated by HC but not on the website and not in progress of release (online supplemental figure 5) can be requested through the website, by providing the following information: drug name (either brand or generic name), manufacturer name (ie, the manufacturer that owns the Drug Identification Number or Notice of Compliance), indication(s)/use of the drug (can be more than one), request of Clinical Information from the initial marketing approval and/or postauthorisation activities, types of studies (adult, paediatric, phase I/II/III studies, effectiveness/safety studies or any combination of the above), reason for request and any additional information and the name and email address of the requester. The request form can be accessed through the front page of the website (online supplemental figures 6 and 7). Importantly, researchers seeking data from the portal do not need to provide a detailed reason or explain their proposed research plans. Rather, they only need to indicate the broad purpose of the research to ensure that the data are not being sought for a commercial purpose.

What are the limitations of the clinical information packages?

While the clinical information packages may contain a large amount of summary-level data, they do not normally provide individual patient-level datasets (IPD) that could be readily used with statistical software, as HC generally does not hold IPD. Some IPD is present in the form of patient-level details found in PDFs, such as adverse event narratives, and concomitant medication lists, and some CSR appendices. This means that researchers

aiming to conduct an IPD meta-analysis will generally find the clinical information packages to not be appropriate as a source of information. The only exception is if the data are available in PDFs, in which case the researchers would first have to convert those patient-level details into analysable datasets.

Additionally, as the packages only contain data submitted by manufacturers for marketing approval, detailed reports of studies conducted by parties other than the sponsor are not included. This limitation is especially important for researchers conducting secondary analyses on older drugs, as there may be numerous studies conducted by parties other than the sponsor that are not contained in the packages.

Overall, for studies that are in the regulator's holdings, the packages provide a far more granular and reliable source of data than peer-reviewed literature.

Key challenges

While the PRCI database contains regulatory data that can be accessed freely by researchers, uptake appears low.^{12 13} Given its growing volume and advantages, it is important to increase the awareness of the PRCI portal. At the same time, the value of the portal (in terms of containing evidence from the premarket phase of a drug's development) may be limited as regulators increasingly rely on postapproval evidence.²⁷ The data contained in the PRCI database will need to be updated and/or connected to other sources of information held by HC as evidence evolves, to ensure data contained are complete and up-to-date when researchers access the data.

Contributors IB wrote the first draft with input from MH, and all authors (IB, PD, MH) made critical revisions to the manuscript. All authors (IB, PD, MH) read and approved the final version of the paper. IB obtained funding for this study. IB is the guarantor for the study.

Funding The study is funded by the Dalhousie Medical School Research in Medicine Studentship.

Competing interests IB has no competing interest to disclose. PD reported running the RIAT Support Center, which was funded by Laura and John Arnold Foundation (2017–2022), and supported part of his university salary. He also reported receiving US FDA funds (via University of Maryland M-CERSI) for supporting graduate students (2020), being an unpaid IMEDS steering committee member (2016–2020), and is an editor at The BMJ (ongoing). In the past 36 months, MH reported being a member of the Patented Medicine Prices Review Board, Canada's national drug price regulator, and receiving honoraria from the Board for his service, and received grants from CIHR (PJT 156256) as well as CIHR and the Public Health Agency of Canada.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Isaac Bai <http://orcid.org/0000-0003-4812-8428>

Peter Doshi <http://orcid.org/0000-0002-7804-4113>

References

- McGauran N, Wieseler B, Kreis J, *et al*. Reporting bias in medical research - a narrative review. *Trials* 2010;11:37.
- Dwan K, Gamble C, Williamson PR, *et al*. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. *PLoS ONE* 2013;8:e66844.
- Lin L, Chu H, Murad MH, *et al*. Empirical comparison of publication bias tests in meta-analysis. *J GEN INTERN MED* 2018;33:1260–7.
- Jefferson T, Doshi P, Boutron I, *et al*. When to include clinical study reports and regulatory documents in systematic reviews. *BMJ Evid Based Med* 2018;23:210–7.
- Food and Drug Administration. *Amendments act of 2007. Public Law No 110-85*. 2007.
- Zarin DA, Fain KM, Dobbins HD, *et al*. 10-year update on study results submitted to Clinicaltrials.gov. *N Engl J Med* 2019;381:1966–74.
- Viergever RF, Karam G, Reis A, *et al*. The quality of registration of clinical trials: still a problem. *PLoS ONE* 2014;9:e84727.
- Loder E, Tovey D, Godlee F. The Tamiflu trials. *BMJ* 2014;348:g2630.
- Schroll JB, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. In: *The Cochrane Collaboration (ed) Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd: Chichester, UK, ED000098.
- Ladanie A, Ewald H, Kasenda B, *et al*. How to use FDA drug approval documents for evidence syntheses. *BMJ* 2018;362:k2815.
- Turner EH. A taxpayer-funded clinical trials registry and results database. *PLoS Med* 2004;1:e60.
- Hodkinson A, Dietz KC, Lefebvre C, *et al*. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. *Syst Rev* 2018;7:117.
- Schroll JB, Bero L, Götzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. *BMJ* 2013;346:f2231.
- Musini V, Lawrence K, Wright J. Using clinical study reports versus published articles in a Cochrane review update. In: *Abstracts of the 24th cochrane colloquium*. Seoul, Korea: John Wiley & Sons, 2016.
- Seife C. Research misconduct identified by the US food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature. *JAMA Intern Med* 2015;175:567–77.
- Demasi M. Rivaroxaban: *Lancet* opens investigation into anticlotting drug trial after *BMJ* report. *BMJ* 2022;379:3071.
- Turner EH. How to access and process FDA drug approval packages for use in research. *BMJ* 2013;347:f5992.

- 18 Ferran J-M, Nevitt SJ. European medicines agency policy 0070: an exploratory review of data utility in clinical study reports for academic research. *BMC Med Res Methodol* 2019;19:204.
- 19 Doshi P, Jefferson T. Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European medicines agency. *Trials* 2016;17:78.
- 20 Health Canada. Guidance document on public release of clinical information. 2019. Available: <https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/profile-public-release-clinical-information-guidance.html> [Accessed 5 Feb 2022].
- 21 Lexchin J, Herder M, Doshi P. Canada finally opens up data on new drugs and devices. *BMJ* 2019;365:l1825.
- 22 Egilman AC, Ross JS, Herder M. Optimizing the data available via health Canada's clinical information portal. *CMAJ* 2021;193:E1305-6.
- 23 Egilman AC, Kapczynski A, McCarthy ME, *et al*. Transparency of regulatory data across the European medicines agency, health Canada, and US food and Drug Administration. *J Law Med Ethics* 2021;49:456-85.
- 24 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. M4: The Common Technical Document, Available: <https://www.ich.org/page/ctd> [Accessed 7 Jul 2021].
- 25 Health Canada. *Public release of clinical information: report on activities during the first year of operation, On file with authors*. 2020.
- 26 Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open* 2013;3:e002496.
- 27 Edmonds S, MacGregor A, Doll A, *et al*. Transparency too little, too late? Why and how health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. *J Law Biosci* 2020;7:lsaa083.
- 28 Herder M. Unlocking health Canada's cache of trade secrets: mandatory disclosure of clinical trial results. *CMAJ* 2012;184:194-9.
- 29 Health Canada. Information for SPIKEVAX - submission control number 253430. Health Canada public release of clinical information. Available: <https://clinical-information.canada.ca/ci-rc/item/253430> [Accessed 17 Dec 2022].
- 30 Health Canada. Information for COMIRNATY - submission control number 252736. Health Canada public release of clinical information. Available: <https://clinical-information.canada.ca/ci-rc/item/252736> [Accessed 17 Dec 2022].